In Vitro Performance of the Wixela Inhub Inhaler Using Severe Chronic Obstructive Pulmonary Disease Patient Inhalation Profiles

BACKGROUND: Wixela Inhub (trademarks of Viatris, Inc.) is a dry powder inhaler (DPI) that delivers a fixed-dose combination of fluticasone propionate and salmeterol and is approved as a generic equivalent to Advair Diskus (trademarks of GlaxoSmithKline plc) for the treatment of asthma and chronic ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Shepherd, Thomas, Kennett, Matthew, Cooper, Andrew, Parkinson, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242708/
https://www.ncbi.nlm.nih.gov/pubmed/34726509
http://dx.doi.org/10.1089/jamp.2021.0017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242708/
https://www.ncbi.nlm.nih.gov/pubmed/34726509
http://dx.doi.org/10.1089/jamp.2021.0017

Ejemplares similares